Propeptide of procollagen type I (PIP) and outcomes in decompensated heart failure

European Journal of Internal Medicine

Volumn 18, Issue 2, 2007, Pages 129-134

  Ruiz Ruiz, Francisco J ^a   Ruiz Laiglesia, Fernando José ^a   Samperiz Legarre, Pilar ^a   Lasierra Diaz, Pilar ^a   Flamarique Pascual, Álvaro ^a   Morales Rull, José L ^a   Perez Calvo, Juan I ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Decompensated heart failure; Prognosis; Propeptide of procollagen type I (PIP)

Indexed keywords

COLLAGEN TYPE 1;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SYSTOLIC DYSFUNCTION;

EID: 33847248904     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.09.014     Document Type: Article

References (31)

1. Weber K.T. Extracellular matrix remodeling in heart failure. Circulation 96 (1997) 4065-4082
2. Pfefer M.A., and Braunwald E. Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 (1990) 1161-1172
3. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 (2000) IV-14-IV-23
4. Zannad F., Dousset B., and Alla F. Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38 (2001) 1227-1232
5. Weber K.T. Monitoring tissue repair and fibrosis from a distance. Circulation 96 (1997) 2488-2492
6. Rodriguez-Artalejo F., Guallar-Castillon P., Banegas J.R., and Del Rey J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 18 (1997) 1771-1779
7. Croft J.B., Giles W.H., Pollard R.A., Keenan N.L., Casper M.L., and Anda R.F. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 159 (1999) 505-510
8. Uusimaa P., Risteli J., Niemela M., Lumme J., Ikaheimo M., Jounela A., et al. Collagen scar formation after acute myocardial infarction: relationship to infarct size, left ventricular function, and coronary artery patency. Circulation 96 (1997) 2565-2572
9. Sato Y., Kataoka K., Matsumori A., Sasayama S., Yamada T., Ito H., et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 78 (1997) 505-508
10. Klappacher G., Franzen P., Haab D., Mehrabi M., Binder M., Plesch K., et al. Measuring extracellular matrix turnover in the serum of patients with idiopatihic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918
11. Rossi A., Cicoira M., Golia G., Zanolla L., Franceschini L., Marino P., et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 90 (2004) 650-654
12. Host N.B., Jensen L.T., Bendixen P.M., Jensen S.E., Koldkjaer O.G., and Simonsen E.E. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 76 (1995) 869-873
13. Cicoira M., Rossi A., Bonapace S., Zanolla L., Golia G., Franceschini L., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 10 (2004) 403-411
14. Poulsen S.H., Host N.B., and Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology 96 (2001) 45-50
15. Querejeta R., Lopez B., Gonzalez A., Sanchez E., Larman M., Martinez Ubago J.L., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110 (2004) 1263-1268
16. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
17. Shamsham F., and Mitchell J. Essentials of the diagnosis of heart failure. Am Fam Physician 61 (2000) 1319-1328
18. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 (2000) 2118-2121
19. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., and Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
20. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
21. Sharma R., Rauchhaus M., Ponikowski P.P., Varney S., Poole-Wilson P.A., Mann D.L., et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36 (2000) 523-528
22. Kirk V., Bay M., Parner J., Krogsgaard K., Herzog T.M., Boesgaard S., et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Eur J Heart Fail 6 (2004) 335-341
23. Alehagen U., Lindstedt G., Levin L.A., and Dahlstrom U. Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 100 (2005) 125-133
24. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) levels improves results. Lancet 355 (2000) 1126-1130
25. Pauschinger M., Knopf D., Petschauser S., Doerner A., Poller W., Schwimmbeck P.L., et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99 (1999) 2750-2756
26. Boluyt M.O., O ́Neill L., Meredith A.L., Bing O.H., Brooks W.W., Conrad C.H., et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ Res 75 (1994) 23-32
27. Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., and Weber K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27 (1993) 2130-2134
28. Brenner D.A., Rippe R.A., Rhodes K., Trotter J.F., and Breindl M. Fibrogenesis and type I collagen gene regulation. J Lab Clin Med 124 (1994) 755-760
29. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., and Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43 (2004) 2028-2035
30. Lamblin N., Susen S., Dagorn J., Mouquet F., Jude B., Van Belle E., et al. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J 150 (2005) 137-143
31. Katz J.N., and Drazner M.H. Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide?. Am Heart J 150 (2005) 1-3